Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T99532
(Former ID: TTDI02010)
|
|||||
Target Name |
HLA class II antigen DR10 (HLA-DRB1)
|
|||||
Synonyms |
MHC class II antigen DRB1*10; HLADRB1; HLA class II histocompatibility antigen, DRB110 beta chain; DRw10
Click to Show/Hide
|
|||||
Gene Name |
HLA-DRB1
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Function |
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete withthose derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading.
Click to Show/Hide
|
|||||
BioChemical Class |
MHC class II
|
|||||
UniProt ID | ||||||
Sequence |
MVCLKLPGGSCMTALTVTLMVLSSPLALSGDTRPRFLWQPKRECHFFNGTERVRFLDRYF
YNQEESVRFDSDVGEFRAVTELGRPDAEYWNSQKDILEQARAAVDTYCRHNYGVVESFTV QRRVQPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFLNGQEEKAGMVSTGLIQNG DWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKMLSGVGGFVLGLL FLGAGLFIYFRNQKGHSGLQPTGFLS Click to Show/Hide
|
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
Reactome | [+] 6 Reactome Pathways | + | ||||
1 | Phosphorylation of CD3 and TCR zeta chains | |||||
2 | Translocation of ZAP-70 to Immunological synapse | |||||
3 | Generation of second messenger molecules | |||||
4 | MHC class II antigen presentation | |||||
5 | PD-1 signaling | |||||
6 | Interferon gamma signaling | |||||
WikiPathways | [+] 4 WikiPathways | + | ||||
1 | MHC class II antigen presentation | |||||
2 | TCR signaling | |||||
3 | Interferon gamma signaling | |||||
4 | Costimulation by the CD28 family |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of Peregrine Pharmaceuticals. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.